Advances in Mycoplasma pneumoniae Infections
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Infectious Diseases".
Deadline for manuscript submissions: closed (31 January 2022) | Viewed by 17146
Special Issue Editors
Interests: pediatric infectious diseases; clinical microbiology (especially Mycoplasma, Chlamydia, and Yersinia); vaccinology
2. Infection Control and Education Center, Nagasaki University Hospital, Nagasaki, Japan
Interests: mycoplasmology; mycology; drug-resistance; infection control
Special Issue Information
Dear Colleagues,
Mycoplasma pneumoniae is the smallest prokaryotic microbe in nature that lacks a cell wall. M. pneumoniae causes various respiratory infections in humans and is a major cause of community‑acquired pneumonia in children as well as adults. The typical clinical presentation is primary atypical pneumonia. In addition, M. pneumoniae can also induce various complications in the blood, cardiovascular system, gastrointestinal tract, and skin, as well as pericarditis, myocarditis, nephritis, and meningitis. Acquired immunity against Mycoplasma pneumoniae does not have lifelong persistence and repeated infection is common. The pathogenic mechanism of M. pneumoniae infection is thought to be mainly due to the immunological involvement of the host; however, the pathogenesis of M. pneumoniae infection is complex and remains to be fully elucidated. Although the first choice of treatment for M. pneumoniae infection is macrolide antibacterial agents, clinically significant acquired macrolide resistance has emerged worldwide and is now complicating treatment. In this Special Issue, I would like to focus on the many new developments over the past few years that have enhanced our understanding of this microbe.
Prof. Dr. Kazunobu Ouchi
Prof. Dr. Koichi Izumikawa
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Mycoplasma pneumoniae
- pathogenesis
- immunity
- epidemiology
- diagnosis
- treatment
- macrolide resistance